NO126738B - - Google Patents
Download PDFInfo
- Publication number
- NO126738B NO126738B NO00214/69A NO21469A NO126738B NO 126738 B NO126738 B NO 126738B NO 00214/69 A NO00214/69 A NO 00214/69A NO 21469 A NO21469 A NO 21469A NO 126738 B NO126738 B NO 126738B
- Authority
- NO
- Norway
- Prior art keywords
- acid
- lower alkyl
- formula
- water
- benzene
- Prior art date
Links
- 239000002253 acid Substances 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000020477 pH reduction Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 57
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- 235000011121 sodium hydroxide Nutrition 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 6
- -1 m-trifluoromethylphenylamino Chemical group 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- HYNJKBCUZJEDNV-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]pyridine-3-carbonyl chloride Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(Cl)=O)=C1 HYNJKBCUZJEDNV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229940043230 sarcosine Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000001562 ulcerogenic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical class CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB327368 | 1968-01-22 | ||
| GB3298868A GB1198551A (en) | 1968-01-22 | 1968-01-22 | New Nicotinuric Acid Derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO126738B true NO126738B (zh) | 1973-03-19 |
Family
ID=26238184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO00214/69A NO126738B (zh) | 1968-01-22 | 1969-01-21 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3538106A (zh) |
| AT (1) | AT287713B (zh) |
| BE (1) | BE726551A (zh) |
| CH (1) | CH495359A (zh) |
| DE (1) | DE1902694C3 (zh) |
| DK (1) | DK125592B (zh) |
| FR (1) | FR2000504A1 (zh) |
| NL (1) | NL159970C (zh) |
| NO (1) | NO126738B (zh) |
| SE (1) | SE351211B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007531753A (ja) * | 2004-03-31 | 2007-11-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非イミダゾール系複素環式化合物 |
| US7777031B2 (en) | 2006-05-30 | 2010-08-17 | Janssen Pharmaceutica Nv | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
| CN101511807A (zh) * | 2006-06-29 | 2009-08-19 | 詹森药业有限公司 | 组胺h3受体的取代的苯甲酰胺调节剂 |
| BRPI0820481A2 (pt) | 2007-11-20 | 2015-06-16 | Janssen Pharmaceutica Nv | Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6604123A (zh) * | 1965-05-28 | 1966-11-29 | ||
| US3415835A (en) * | 1966-06-21 | 1968-12-10 | Hoffmann La Roche | 2-lower-alkanoyl-amido-nicotinic acid and derivatives thereof |
-
1969
- 1969-01-07 BE BE726551D patent/BE726551A/xx not_active IP Right Cessation
- 1969-01-10 US US790477A patent/US3538106A/en not_active Expired - Lifetime
- 1969-01-14 FR FR6900427A patent/FR2000504A1/fr active Pending
- 1969-01-20 SE SE00691/69A patent/SE351211B/xx unknown
- 1969-01-21 DK DK32269AA patent/DK125592B/da unknown
- 1969-01-21 DE DE1902694A patent/DE1902694C3/de not_active Expired
- 1969-01-21 NL NL6900954.A patent/NL159970C/xx not_active IP Right Cessation
- 1969-01-21 CH CH84969A patent/CH495359A/fr not_active IP Right Cessation
- 1969-01-21 NO NO00214/69A patent/NO126738B/no unknown
- 1969-01-22 AT AT00643/69A patent/AT287713B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CH495359A (fr) | 1970-08-31 |
| SE351211B (zh) | 1972-11-20 |
| NL159970B (nl) | 1979-04-17 |
| NL6900954A (zh) | 1969-07-24 |
| FR2000504A1 (zh) | 1969-09-12 |
| AT287713B (de) | 1971-02-10 |
| DK125592B (da) | 1973-03-12 |
| US3538106A (en) | 1970-11-03 |
| NL159970C (nl) | 1979-09-17 |
| BE726551A (zh) | 1969-06-16 |
| DE1902694B2 (de) | 1977-10-06 |
| DE1902694A1 (de) | 1969-09-04 |
| DE1902694C3 (de) | 1978-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3288797A (en) | Lipoic acid derivatives and their preparation | |
| US4192878A (en) | Derivatives of thiazolidinecarboxylic acids and related acids | |
| HU195770B (en) | Process for production of derivatives of sulphonilamino-ethil and medical compositions containing them as active substance | |
| NO134115B (zh) | ||
| JP2010513376A (ja) | 肝カルニチンパルミトイルトランスフェラーゼ（ｌ−ｃｐｔｉ）としてのスルホンアミド誘導体 | |
| EP1474427A1 (en) | Polymorphs of clopidogrel hydrochloride and their use as antithrombic compounds | |
| US3624103A (en) | 3-indoleacetohydroxamic acids | |
| WO2020107500A1 (zh) | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 | |
| JPS63141984A (ja) | チエノピリジノン誘導体 | |
| NL8201145A (nl) | Werkwijze ter bereiding van een farmaceutisch preparaat alsmede werkwijze ter bereiding van daarvoor geschikte verbindingen. | |
| IL25505A (en) | Aminothiophene derivatives and process for their manufacture | |
| CN103193864B (zh) | 培哚普利的精氨酸盐的δ晶型、其制备方法和包含它的药物组合物 | |
| NO152414B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2,6-dialkoksybenzamider | |
| NO126738B (zh) | ||
| PT753511E (pt) | Derivados de acido 4-indol-1-butirico, sua preparacao e utilizacao como inibidores dos receptores alfa-1-adrenergicos e das 5-alfa-redutases da testosterona | |
| NO831562L (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive kinolinderivater | |
| GB2038800A (en) | Antihypertensive sulphurcontaining compounds | |
| US4282235A (en) | Derivatives of thiazolidinecarboxylic acids and related acids | |
| NO131930B (zh) | ||
| PT88116B (pt) | Processo de preparacao de derivados de acido naftalenopropionico uteis como agentes anti-inflamatorios/antialergicos | |
| HU204520B (en) | Process for producing pharmaceutically active compounds and pharmaceutical compositions containing them | |
| NO751401L (zh) | ||
| NO893653L (no) | Quinolinderivater og deres fremstilling. | |
| JPS6313985B2 (zh) | ||
| US4237129A (en) | Derivatives of thiazolidinecarboxylic acids and related acids |